This FOA would support investigations with a minimum of two relevant co-pathologies (e.g., tau, alpha-synuclein, TDP-43, TMEM106B, vascular), with optional risk factors and co-morbidities, to identify cellular and molecular mechanisms of how/why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes. Studies should examine co-pathology cellular and molecular interactions across brain regions and time in proximate cell population, across various intracellular dynamics and localization, and upstream and downstream from aggregated protein states to determine what events lead to worse phenotypic outcomes.
Find Funding Opportunities
COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.
Learn more about award types and program directors and managers.
NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!
For more focused results add quotes to indicate parameters. Example format: "search term".
Expiration Date: Thursday, October 5, 2023 NOFO Number: PAR-23-211 Release Date: Tuesday, May 23, 2023 Notice Type: PAR
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)Expiration Date: Thursday, October 5, 2023 NOFO Number: PAR-23-212 Release Date: Tuesday, May 23, 2023 Notice Type: PAR
This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS.
Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed)Expiration Date: Saturday, July 29, 2023 NOFO Number: RFA-NS-24-003 Release Date: Friday, May 19, 2023 Notice Type: RFA
This Notice of Funding Opportunity (NOFO) invites applications for a multisite study to comprehensively characterize ADRD relevant pathology related to cognitive impairment and dementia outcomes in persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual (sex, age at time of injury, time since injury, social determinants of health, etc.) and injury characteristics (injury severity and frequency) to describe associations between neuropathological burden and antemortem clinicopathologic symptoms and outline the prevalence of TBI-related ADRD diagnoses, and CTE pathology in the participating brain banks. This NOFO intends to support applications that include retrospective samples, plans to acquire new brain tissue specimens, and methods to assess the antemortem symptomatology and clinical presentation. To further advance research in the area, broad sharing of clinical and neuropathological data will be a critical feature of successful applications, including the development of a digital resource for distribution and sharing of assessed neuropathological tissue.
Emergency Medicine Research Career Development Program in the Neurological Sciences (EMRCDP-NS) (K12 - No Independent Clinical Trial Allowed)Expiration Date: Thursday, August 10, 2023 NOFO Number: PAR-23-151 Release Date: Tuesday, May 16, 2023 Notice Type: PAR
The purpose of this funding opportunity announcement (FOA) is to invite applications to support a national program of mentored research career development for junior emergency medicine faculty at institutions nationwide that support emergency medicine physicians to conduct research. The goal of the program is to expand the cadre of emergency medicine investigators trained to conduct research into neurological disorders, which makes use of their expertise associated with their clinical experience as emergency medicine clinicians.
Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)Expiration Date: Wednesday, October 9, 2024 NOFO Number: RFA-NS-23-027 Release Date: Monday, May 15, 2023 Notice Type: RFA
Reissue of RFA-NS-22-011 to comply with DMSP changes. No changes to receipt dates or locus of review. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)Expiration Date: Saturday, September 9, 2023 NOFO Number: RFA-NS-24-010 Release Date: Monday, May 15, 2023 Notice Type: RFA
This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
HEAL Initiative Partnerships to Advance INterdisciplinary (PAIN) Training in Clinical Pain Research: The HEAL PAIN Cohort Program (T90/R90 Independent Clinical Trial Not Allowed)Expiration Date: Wednesday, September 27, 2023 NOFO Number: RFA-NS-24-015 Release Date: Tuesday, May 9, 2023 Notice Type: RFA
This concept would support the development of pain clinical trainees as a means of enhancing the clinical pain workforce. It would fund 4 clinical pain T90/R90s that would provide robust post-doctoral fellowship research training in areas of clinical pain management that would benefit from further research. The T90/R90 mechanism is a NRSA program that supports comprehensive interdisciplinary research training programs at the undergraduate, predoctoral, and/or post-doctoral levels by capitalizing on the infrastructure of existing multidisciplinary and interdisciplinary research programs. The HEAL T90/R90 program would focus on training post-doctoral fellows with T90 trainees being those who are NRSA eligible and R90 trainees (maximum of 1 per award per year) being those who do not meet qualifications for NRSA support (including non-US citizens or residents). Trainees would either need to have a clinical degree or have a non-clinical degree but are interested in conducting clinical pain research. The T90/R90 training programs would provide mentoring and training to promote the successful transition of the trainees to independent research careers in academic or government settings. Unlike the T32 mechanism, the T90/R90 mechanism would support the dedication of 10% of the programs mentors time to mentoring the next generation of clinical pain researchers. The newly funded T90/R90s would work in coordination with the HEAL R24 Coordinating Center to ensure that trainees participate in the network, collaborative events/webinars, build relationships with basic and clinical science trainees, and attend the annual workshop. The NIH will prioritize funding T90/R90s universities and institutions that do not currently have a pain T32 or have not previously received funding for a pain T32. T90/R90 applicants are encouraged to partner with another university or institution to help increase the interdisciplinary nature of the mentors and trainees.
Expiration Date: Wednesday, May 8, 2024 NOFO Number: PAR-23-142 Release Date: Monday, May 8, 2023 Notice Type: PAR
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)Expiration Date: Thursday, June 8, 2023 NOFO Number: RFA-MH-23-290 Release Date: Monday, May 8, 2023 Notice Type: RFA
This is a reissue of RFA-MH-21-175 to comply with DMSP policy. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.
Expiration Date: Wednesday, May 8, 2024 NOFO Number: PAR-23-143 Release Date: Monday, May 8, 2023 Notice Type: PAR
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field.This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.